Welcome to our dedicated page for ICU MEDICAL INC/DE SEC filings (Ticker: ICUI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ICU MEDICAL INC/DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ICU MEDICAL INC/DE's regulatory disclosures and financial reporting.
ICU MEDICAL INC/DE (ICUI) reported that Virginia Ruth Sanzone, its VP, General Counsel, sold a total of 4,856 shares of common stock on September 3, 2026 in four open-market or private transactions pursuant to a Rule 10b5-1 trading plan adopted on June 8, 2026, at weighted average prices ranging from about $167.67 to $171.52 per share.
ICU Medical Inc. (ICUI) has a notice filed under Rule 144 for a proposed resale of its common stock by company officer Virginia Ruth Sanzone. The notice covers 4,856 shares of common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ.
The shares were acquired upon the vesting of Restricted Stock and Performance Shares during the period from March 15, 2024 through March 15, 2026, with an indicated aggregate market value of approximately $819,150.33 tied to the proposed sale quantity.
ICU MEDICAL INC/DE (ICUI) reported that Chief Financial Officer Brian Michael Bonnell sold 6,381 shares of common stock on September 1, 2026, at $175.00 per share in an open-market or private transaction. After this sale, he directly holds 56,062 shares. The sale was described as involving restricted award shares and was effected under a Rule 10b5-1 trading plan adopted on June 1, 2026, with all shares sold at the exact disclosed price.
ICU Medical, Inc. (ICUI) officer Brian Michael Bonnell filed a notice under Rule 144 to sell common stock. The filing lists up to 6,381 shares of ICUI common stock to be sold through Morgan Stanley Smith Barney, with an aggregate market value of $1,116,675.00 and an approximate sale date of September 1, 2026. The shares derive from restricted stock and performance share awards granted between 2022 and 2024. The notice also reports that Bonnell sold 9,307 shares of ICUI common stock during the past three months for total proceeds of $1,608,142.82.
ICU MEDICAL INC/DE (ICUI) reported that Chief Financial Officer Brian Michael Bonnell sold a total of 9,307 shares of common stock on August 31, 2026 in four open-market transactions. The sales, related to a restricted award, were effected under a Rule 10b5-1 trading plan adopted on June 1, 2026, at weighted average prices ranging from about $170.57 to $174.08 per share, each executed over multiple trades within the stated price ranges.
ICU MEDICAL, INC. (ICUI) received a notice that officer Brian Michael Bonnell intends to sell common stock under Rule 144. The planned sale covers 9,307 shares of ICUI common stock through Morgan Stanley Smith Barney LLC on or after 08/31/2026, listed on NASDAQ.
The shares were acquired from the issuer upon vesting of Restricted Stock and Performance Shares originally granted on 08/16/2019, with vesting occurring between 08/16/2019 and 03/06/2023. The filing reports an aggregate market value of about $1,608,142.82 for the shares to be sold and indicates no ICUI shares sold by this person in the past three months.
Fuller & Thaler Asset Management, Inc., a California corporation, reports beneficial ownership of common stock of ICU Medical, Inc. on an amended Schedule 13G filing. The firm holds 1,298,126.96 shares, representing 5.19% of the company’s outstanding common stock.
Fuller & Thaler reports sole voting power over 1,276,819.96 shares and sole dispositive power over 1,298,126.96 shares, with no shared voting or dispositive power. The amendment is signed by Chief Compliance Officer Hanna Zanoni on August 14, 2026.
ICU Medical Inc. (ICUI) officer Daniel Woolson, VP and GM-Infusion Capital, reported a sale of 5,417 shares of common stock on August 13, 2026 at $181.33 per share. Following this transaction, he directly holds 17,062 shares of ICU Medical common stock. The Rule 10b5-1 trading plan checkbox was not marked.
ICU Medical shareholder Daniel Woolson filed to sell 5,417 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $982,264.61, expected on 08/13/2026 on NASDAQ. In the past three months, Woolson reported selling 2,123 shares on 05/22/2026 for $280,684.80. The filing also lists multiple sources of these shares, including performance stock units and restricted stock vesting under a registered plan with various grant or vesting dates and share amounts.
Janus Henderson Group Ltd. reports beneficial ownership of 2,781,621 shares of ICU Medical, Inc. common stock, representing 11.1% of the class. All of these shares are reported with shared voting power and shared dispositive power, with no sole voting or dispositive authority.
Janus Henderson is the ultimate parent of multiple investment advisers and related entities (the Asset Managers) that exercise investment and/or voting discretion for their clients, referred to as Managed Portfolios. The Asset Managers may be deemed the beneficial owners of the ICU Medical shares due to this discretion but disclaim rights to receive dividends or sale proceeds, which belong to the Managed Portfolios. No single Managed Portfolio owns more than five percent of ICU Medical’s common stock.